Literature DB >> 33073320

Feasibility of exercise treadmill 13N-ammonia positron emission tomography myocardial perfusion imaging using an off-site cyclotron.

Daniel R Harland1, Patrycja Z Galazka2, Jerry Rasmussen3, Debra Mahlum2, Janelle Falk2, Steven C Port2.   

Abstract

BACKGROUND: Myocardial perfusion imaging with treadmill exercise nitrogen-13 (13N)-ammonia positron emission tomography (PET) presents a logistical challenge. We investigated the feasibility of exercise treadmill (GXT) 13N-ammonia PET MPI using an off-site cyclotron for production of 13N-ammonia.
METHODS: Thirty-three patients underwent GXT 13N-ammonia PET MPI over 23 months. 13N-ammonia doses were prepared at an off-site cyclotron. Patients underwent 13N-ammonia resting and 13N-ammonia GXT emission and transmission scans at our facility. Image quality, perfusion data, and clinical variables were evaluated.
RESULTS: We analyzed 33 patients (7/26 female/male). Mean age was 63 ± 12 years and mean BMI was 33.7 ± 6.9. GXT PET was feasible in all patients. Image quality was good in 29 patients, adequate in 3, and severely compromised in 1 patient. Summed stress score was 4.5 ± 5.7. Resting and GXT left ventricular ejection fractions were 63.7 ± 10.9% and 66.3 ± 13.1%. TID ratio was 1.0 ± 0.1.
CONCLUSIONS: Treadmill exercise 13N-ammonia PET is feasible in a large medical center without access to an on-site cyclotron. This technique requires close coordination with an off-site cyclotron but expands the role of PET to patients for whom exercise is more appropriate than pharmacologic stress imaging.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  13N-ammonia; PET; cyclotron; exercise

Mesh:

Substances:

Year:  2020        PMID: 33073320     DOI: 10.1007/s12350-020-02366-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  1 in total

1.  Initial clinical experience of N13-ammonia myocardial perfusion PET/CT using a compact superconducting production system.

Authors:  Justin Pieper; Vaiibhav N Patel; Richard L Weinberg; Venkatesh L Murthy; Sylvia Escolero; Jacob R Nelson; Alexis Poitrasson-Rivière; Christopher K Shreves; Nick Freiburger; David Hubers; Jill Rothley; James R Corbett; Joseph Oliverio; Edward P Ficaro
Journal:  J Nucl Cardiol       Date:  2019-09-12       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.